Compare OXSQ & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | CGEN |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.4M | 125.3M |
| IPO Year | N/A | 2000 |
| Metric | OXSQ | CGEN |
|---|---|---|
| Price | $1.84 | $1.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 728.9K | 286.4K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 22.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,142,565.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.12 | $208.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.56 | $1.13 |
| 52 Week High | $2.87 | $2.66 |
| Indicator | OXSQ | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 43.72 |
| Support Level | $1.84 | $1.51 |
| Resistance Level | $1.91 | $1.66 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 18.00 | 17.86 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.